dobutamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics 937 34368-04-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dobutamine
  • dobutamine hydrochloride
  • dobutamine HCl
A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.
  • Molecular weight: 301.39
  • Formula: C18H23NO3
  • CLOGP: 2.43
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 72.72
  • ALOGS: -4.34
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.13 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance) 115 mL/min/kg Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 18, 1978 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Stress cardiomyopathy 175.58 27.54 50 3705 9400 63475867
Cardiogenic shock 140.19 27.54 49 3706 17883 63467384
Drug ineffective 96.91 27.54 198 3557 1044567 62440700
Multiple organ dysfunction syndrome 83.32 27.54 48 3707 56704 63428563
Cardiac failure 63.54 27.54 48 3707 89094 63396173
Toxic epidermal necrolysis 55.57 27.54 28 3727 25306 63459961
Vasoplegia syndrome 55.24 27.54 14 3741 1685 63483582
Local anaesthetic systemic toxicity 53.10 27.54 12 3743 887 63484380
Septic shock 45.51 27.54 35 3720 66594 63418673
Drug ineffective for unapproved indication 45.17 27.54 27 3728 34036 63451231
Pulmonary hypertension 43.03 27.54 27 3728 37096 63448171
Ventricular tachycardia 40.66 27.54 21 3734 19958 63465309
Cardiac arrest 37.41 27.54 36 3719 92509 63392758
Ureaplasma infection 34.74 27.54 8 3747 643 63484624
Status epilepticus 33.87 27.54 17 3738 15216 63470051
Renal failure 31.91 27.54 37 3718 117615 63367652
Ventricular fibrillation 31.66 27.54 15 3740 11852 63473415
Stevens-Johnson syndrome 31.07 27.54 19 3736 24931 63460336
Pulmonary arterial hypertension 30.19 27.54 18 3737 22559 63462708
Fatigue 29.73 27.54 8 3747 888020 62597247
Renal impairment 29.51 27.54 31 3724 88324 63396943
Respiratory failure 29.25 27.54 33 3722 101825 63383442

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 523.48 31.00 150 6844 8451 34941486
Appendicitis 451.12 31.00 152 6842 14655 34935282
Multiple organ dysfunction syndrome 403.52 31.00 227 6767 76339 34873598
Stress 394.44 31.00 167 6827 30180 34919757
Ventricular fibrillation 313.69 31.00 131 6863 22823 34927114
Ascites 303.02 31.00 159 6835 46412 34903525
Abdominal distension 258.64 31.00 155 6839 58337 34891600
Blood phosphorus increased 225.94 31.00 77 6917 7644 34942293
Hyponatraemia 207.47 31.00 154 6840 82537 34867400
General physical health deterioration 178.59 31.00 170 6824 128099 34821838
Sepsis 174.08 31.00 189 6805 166372 34783565
Constipation 136.92 31.00 152 6842 136830 34813107
Abdominal pain 118.26 31.00 154 6840 163464 34786473
Dry mouth 112.84 31.00 72 6922 30093 34919844
Myasthenia gravis 99.30 31.00 41 6953 6899 34943038
Blood uric acid increased 98.87 31.00 45 6949 9579 34940358
Off label use 88.37 31.00 231 6763 419293 34530644
Vomiting 76.82 31.00 159 6835 247462 34702475
Toxic epidermal necrolysis 71.93 31.00 48 6946 21598 34928339
Drug ineffective 67.68 31.00 222 6772 456529 34493408
Stress cardiomyopathy 65.96 31.00 22 6972 2037 34947900
Hyperphosphataemia 59.38 31.00 25 6969 4412 34945525
Fatigue 58.83 31.00 4 6990 370649 34579288
Condition aggravated 57.82 31.00 122 6872 192074 34757863
Blood cholesterol increased 57.51 31.00 41 6953 20502 34929435
Analgesic therapy 54.36 31.00 16 6978 982 34948955
Drug therapy 52.24 31.00 16 6978 1125 34948812
Incorrect route of product administration 51.92 31.00 34 6960 14811 34935126
Cardiogenic shock 50.16 31.00 42 6952 26576 34923361
Nausea 49.04 31.00 164 6830 339744 34610193
Platelet distribution width increased 48.53 31.00 10 6984 134 34949803
Sleep disorder therapy 45.37 31.00 14 6980 1009 34948928
Somnolence 43.63 31.00 79 6915 111037 34838900
Iron deficiency 42.49 31.00 21 6973 5360 34944577
Ventricular tachycardia 36.33 31.00 35 6959 26544 34923393
Neuralgia 33.00 31.00 26 6968 15087 34934850

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 583.80 25.15 149 10162 8402 79725675
Multiple organ dysfunction syndrome 468.23 25.15 252 10059 119994 79614083
Appendicitis 461.02 25.15 151 10160 20643 79713434
Ventricular fibrillation 372.57 25.15 144 10167 31782 79702295
Ascites 318.03 25.15 167 10144 75395 79658682
Stress 315.44 25.15 169 10142 79443 79654634
Blood phosphorus increased 248.91 25.15 80 10231 10267 79723810
Abdominal distension 237.36 25.15 163 10148 119487 79614590
Sepsis 209.05 25.15 213 10098 269215 79464862
Stress cardiomyopathy 207.25 25.15 71 10240 11095 79722982
Hyponatraemia 164.60 25.15 155 10156 177693 79556384
Cardiogenic shock 157.47 25.15 86 10225 41828 79692249
Drug ineffective 149.94 25.15 387 9924 1080526 78653551
General physical health deterioration 145.12 25.15 178 10133 275060 79459017
Constipation 119.37 25.15 164 10147 282886 79451191
Toxic epidermal necrolysis 108.25 25.15 69 10242 44512 79689565
Blood uric acid increased 103.52 25.15 45 10266 13315 79720762
Myasthenia gravis 100.54 25.15 41 10270 10358 79723719
Off label use 97.80 25.15 297 10014 906918 78827159
Fatigue 81.13 25.15 12 10299 929715 78804362
Abdominal pain 80.60 25.15 164 10147 389405 79344672
Dry mouth 72.38 25.15 72 10239 87947 79646130
Ventricular tachycardia 66.60 25.15 50 10261 41885 79692192
Hyperphosphataemia 61.15 25.15 25 10286 6351 79727726
Analgesic therapy 61.09 25.15 16 10295 993 79733084
Vasoplegia syndrome 59.31 25.15 21 10290 3609 79730468
Drug therapy 58.33 25.15 16 10295 1185 79732892
Condition aggravated 56.42 25.15 167 10144 500957 79233120
Platelet distribution width increased 52.82 25.15 10 10301 135 79733942
Sleep disorder therapy 51.40 25.15 14 10297 1010 79733067
Cardiac failure 46.90 25.15 77 10234 154765 79579312
Arthralgia 46.19 25.15 9 10302 571794 79162283
Right ventricular failure 44.08 25.15 31 10280 23466 79710611
Local anaesthetic systemic toxicity 41.88 25.15 12 10299 1042 79733035
Status epilepticus 40.06 25.15 30 10281 25011 79709066
Incorrect route of product administration 39.19 25.15 34 10277 34895 79699182
Iron deficiency 37.60 25.15 21 10290 10633 79723444
Drug ineffective for unapproved indication 36.81 25.15 39 10272 51199 79682878
Fall 36.67 25.15 9 10302 487620 79246457
Hypernatraemia 36.63 25.15 23 10288 14428 79719649
Vomiting 34.90 25.15 174 10137 665654 79068423
Renal injury 33.31 25.15 23 10288 16904 79717173
Low cardiac output syndrome 33.18 25.15 10 10301 1035 79733042
Dizziness 32.07 25.15 14 10297 526427 79207650
Eosinophilic myocarditis 31.64 25.15 10 10301 1212 79732865
Fear 30.06 25.15 24 10287 21962 79712115
Ventricular arrhythmia 30.05 25.15 17 10294 8823 79725254
Somnolence 30.04 25.15 83 10228 238898 79495179
Electrocardiogram ST segment elevation 28.14 25.15 16 10295 8381 79725696
Weight decreased 27.79 25.15 6 10305 355192 79378885
Asthenia 27.57 25.15 16 10295 511673 79222404
Renal impairment 27.40 25.15 62 10249 157721 79576356
Myoclonus 27.21 25.15 25 10286 27635 79706442
Cardiac arrest 27.02 25.15 65 10246 172031 79562046
Septic shock 26.83 25.15 53 10258 122748 79611329
Renal failure 26.45 25.15 71 10240 200897 79533180
Cardiomyopathy 26.37 25.15 25 10286 28749 79705328
Pulmonary alveolar haemorrhage 25.98 25.15 17 10294 11440 79722637

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01CA07 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Adrenergic and dopaminergic agents
FDA MoA N0000000245 Adrenergic beta-Agonists
FDA EPC N0000175555 beta-Adrenergic Agonist
CHEBI has role CHEBI:35522 beta-adrenergic agonists
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:38147 cardiotonic drugs
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058665 Adrenergic beta-1 Receptor Agonists
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D020011 Protective Agents
MeSH PA D013566 Sympathomimetics

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Cardiogenic shock indication 89138009
Decompensated cardiac failure indication 195111005
Stress echocardiography using dobutamine indication 703338002
Cardiac Decompensation indication
Cardiac Decompensation Post Cardiac Surgery indication
Organic Cardiac Disease indication
Ventricular premature beats contraindication 17338001
Myocardial infarction contraindication 22298006 DOID:5844
Hypovolemia contraindication 28560003
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Atrial fibrillation contraindication 49436004 DOID:0060224
Aortic valve stenosis contraindication 60573004 DOID:1712
Idiopathic hypertrophic subaortic stenosis contraindication 360465008




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.98 acidic
pKa2 10.59 acidic
pKa3 13.49 acidic
pKa4 9.03 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR AGONIST EC50 5.50 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR AGONIST EC50 6.20 WOMBAT-PK CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.98 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.00 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 6.42 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.87 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 5.77 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 6.91 DRUG MATRIX
Carbonic anhydrase 2 Enzyme Ki 6.32 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 7.35 DRUG MATRIX
Carbonic anhydrase 1 Enzyme Ki 5.72 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 5.05 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 5.01 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 5.36 CHEMBL
Epidermal growth factor receptor Kinase IC50 5.26 DRUG MATRIX
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.14 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 6.05 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 5.37 CHEMBL
Tyrosine-protein kinase Lck Kinase IC50 5.26 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.40 DRUG MATRIX
Catechol O-methyltransferase Enzyme Km 4.30 WOMBAT-PK
Carbonic anhydrase 3 Enzyme Ki 5.13 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 5.02 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 4.92 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 5.38 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 5.02 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 6.22 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 6.73 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.80 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 6.96 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 6.41 CHEMBL

External reference:

IDSource
4019730 VUID
N0000147822 NUI
D00632 KEGG_DRUG
49745-95-1 SECONDARY_CAS_RN
203121 RXNORM
4017541 VANDF
4019730 VANDF
C0012963 UMLSCUI
CHEBI:4670 CHEBI
Y00 PDB_CHEM_ID
CHEMBL926 ChEMBL_ID
DB00841 DRUGBANK_ID
CHEMBL1200418 ChEMBL_ID
D004280 MESH_DESCRIPTOR_UI
36811 PUBCHEM_CID
535 IUPHAR_LIGAND_ID
3340 INN_ID
3S12J47372 UNII
2871 MMSL
4625 MMSL
d00215 MMSL
000614 NDDF
000615 NDDF
26523005 SNOMEDCT_US
387145002 SNOMEDCT_US
90118002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 0143-9141 INJECTION, SOLUTION 12.50 mg INTRAVENOUS ANDA 20 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1073 INJECTION 100 mg INTRAVENOUS NDA 18 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1073 INJECTION 100 mg INTRAVENOUS NDA 18 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1075 INJECTION 200 mg INTRAVENOUS NDA 18 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1075 INJECTION 200 mg INTRAVENOUS NDA 18 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1077 INJECTION 400 mg INTRAVENOUS NDA 18 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1077 INJECTION 400 mg INTRAVENOUS NDA 18 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0409-2344 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 21 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0409-2344 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 21 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-2346 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 12 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-2347 INJECTION, SOLUTION 200 mg INTRAVENOUS NDA 12 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-3724 INJECTION, SOLUTION 400 mg INTRAVENOUS NDA 12 sections
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 14335-171 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 21 sections
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 14335-172 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 21 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 50090-4562 INJECTION 400 mg INTRAVENOUS NDA 18 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1330 INJECTION, SOLUTION 200 mg INTRAVENOUS NDA 12 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1330 INJECTION, SOLUTION 200 mg INTRAVENOUS NDA 12 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1337 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 12 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1337 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 12 sections
DOBUTAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1566 INJECTION 100 mg INTRAVENOUS NDA 11 sections
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 54868-5717 INJECTION, SOLUTION 12.50 mg INTRAVENOUS ANDA 11 sections
Dobutamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-5777 INJECTION, SOLUTION 400 mg INTRAVENOUS NDA 12 sections
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 62778-350 INJECTION, SOLUTION 12.50 mg INTRAVENOUS ANDA 2 sections
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 70436-203 INJECTION 250 mg INTRAVENOUS ANDA 21 sections